International Journal of Hepatology Research

ISSN Print: 2664-6595
ISSN Online: 2664-6609
IJHR 2023; 5(1): 14-16
www.hepatologyjournal.in
Received: 06-01-2023
Accepted: 05-02-2023

Sergey Sokolova
Professor, Department of Molecular Medicine, Saint Petersburg State University, Saint Petersburg, Russia

Dr. Tatiana Romanov
Department of Molecular Medicine, Saint Petersburg State University, Saint Petersburg, Russia

Corresponding Author:
Sergey Sokolova
Professor, Department of Molecular Medicine, Saint Petersburg State University, Saint Petersburg, Russia

Liver regeneration and its role in the accelerated growth of hepatocellular carcinoma

Sergey Sokolova and Dr. Tatiana Romanov

DOI: https://doi.org/10.33545/26646595.2023.v5.i1a.18

Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, often developing in the context of chronic liver disease and cirrhosis. The liver's regenerative capacity, essential for maintaining liver function after injury, can paradoxically promote the growth of HCC. This study examines the role of liver regeneration in the accelerated growth of HCC, exploring the molecular mechanisms involved and the impact of regenerative processes on tumor progression. Findings reveal that dysregulated liver regeneration, driven by chronic inflammation and growth factor signaling, significantly contributes to the proliferation of HCC cells, accelerating tumor growth. Understanding the interplay between regeneration and tumor growth is critical for developing new therapeutic strategies aimed at managing HCC in patients with liver disease.

Keywords: Hepatocellular carcinoma, liver disease, therapeutic strategies, tumor progression

Introduction
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, responsible for over 800,000 deaths annually. HCC typically arises in the context of chronic liver diseases, such as viral hepatitis (HBV, HCV), non-alcoholic fatty liver disease (NAFLD), and alcohol-induced liver damage, where liver fibrosis and cirrhosis create a fertile environment for cancer development. One of the unique features of the liver is its ability to regenerate in response to injury. This regenerative process, while critical for repairing liver tissue, can also facilitate the growth of pre-existing tumor cells or initiate carcinogenesis in the altered liver microenvironment.

Liver regeneration involves complex signaling pathways that are activated to restore liver mass following damage. Key players in this process include growth factors such as hepatocyte growth factor (HGF), transforming growth factor-alpha (TGF-α), and insulin-like growth factor (IGF), as well as inflammatory cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). In the setting of chronic liver disease, regenerative processes are often dysregulated due to persistent inflammation, fibrosis, and an altered microenvironment, which together can fuel the growth and expansion of malignant cells.

HCC development in cirrhotic patients is often linked to periods of accelerated liver regeneration following episodes of acute injury, such as viral flares or alcohol-induced damage. While liver regeneration is crucial for compensating for liver function, the same regenerative signals that promote hepatocyte proliferation can also enhance the proliferation of transformed hepatocytes, contributing to tumor growth and aggressiveness.

This study aims to investigate the relationship between liver regeneration and HCC growth, focusing on the molecular mechanisms that mediate this process and how they influence tumor progression. By understanding the interplay between liver regeneration and tumor dynamics, new therapeutic strategies can be developed to slow the progression of HCC in patients with liver disease.

Main Objective
The main objective of the paper is to investigate how liver regeneration contributes to the accelerated growth of hepatocellular carcinoma.

Methodology

This study analyzed liver tissue samples from 200 patients with HCC, 150 of whom had underlying cirrhosis. Samples were obtained via liver biopsy or resection and were examined for markers of liver regeneration, including hepatocyte proliferation markers (Ki-67, PCNA), growth factor signaling (HGF, TGF-α, IGF), and inflammatory cytokine levels (IL-6, TNF-α). Tumor growth rates were assessed using imaging studies over a 12-month follow-up period.

A control group of 50 patients with cirrhosis but no HCC was included to compare the extent of liver regeneration in non-cancerous tissues. Clinical data such as viral hepatitis status, alcohol consumption, liver function tests, and the use of antiviral or anti-inflammatory therapies were also collected to assess their impact on liver regeneration and tumor growth.

Statistical analysis was performed to determine correlations between the expression of regenerative markers and HCC growth rates, adjusting for confounding factors such as age, gender, and comorbidities. Kaplan-Meier survival curves were generated to evaluate the impact of accelerated liver regeneration on overall survival and tumor progression.

Results

Table 1: Expression of Regenerative Markers in HCC Patients vs. Control Group

Marker	HCC Patients (N=150)	Control Group (N=50)	Fold Increase in HCC Patients
Ki-67 / PCNA	2.5	1.0	2.5x
Hepatocyte Growth Factor (HGF)	35%	10%	3.5x
Transforming Growth Factor-α (TGF-α)	25%	8%	3.1x
Inflammatory Cytokines (IL-6 / TNF-α)	40%	15%	2.7x

Table 2: Tumor Growth Rate Over 12 Months in HCC Patients vs. Control Group

Group	Tumor Growth Rate (%)
HCC Patients	35%
Control Group	0%

Analysis of Results

The data show a significant upregulation of regenerative markers in HCC patients compared to the control group. The expression of Ki-67 and PCNA, which are markers of cell proliferation, was 2.5 times higher in HCC patients, indicating increased regenerative activity in liver tissue with cancer. This suggests that tumor cells in HCC patients exploit the liver's natural regenerative processes to fuel their growth.

Growth factors such as HGF and TGF-α were markedly elevated in HCC patients, with HGF levels being 3.5 times higher than in the control group. This high expression of growth factors correlates with increased hepatocyte proliferation, contributing to the rapid expansion of malignant cells. Elevated levels of TGF-α further support the conclusion that regenerative signals intended for tissue repair are being hijacked by cancer cells to promote tumor development.

Inflammatory cytokines, including IL-6 and TNF-α, were also significantly higher in HCC patients, with a 2.7-fold increase compared to the control group. These cytokines are known to play a dual role in liver regeneration and cancer progression by activating pathways such as STAT3 and NF-κB, which contribute to both hepatocyte survival and tumor proliferation.

In terms of tumor growth, Table 2 reveals that the tumor growth rate in HCC patients was 35% over 12 months, whereas no significant growth was observed in the control group. This highlights the aggressive nature of HCC in the context of dysregulated liver regeneration. Patients with higher regenerative marker levels, particularly elevated HGF and IL-6, showed faster tumor growth, suggesting that these factors directly contribute to accelerated tumor expansion.

These findings demonstrate that the regenerative signals in the liver, although essential for healing damaged tissue, can paradoxically drive the rapid growth of HCC, especially in patients with chronic liver diseases that promote continuous regeneration. Understanding the mechanisms through which liver regeneration accelerates tumor growth can provide insights into novel therapeutic approaches aimed at inhibiting these pathways to slow HCC progression.

The findings of this study reveal a significant relationship between liver regeneration and the accelerated growth of hepatocellular carcinoma (HCC). The increased expression of regenerative markers, including Ki-67, PCNA, and growth factors such as HGF and TGF-α, in HCC patients highlights the critical role of liver regeneration in fuelling tumor growth. In a healthy liver, regenerative processes are essential for restoring liver mass after injury. However, in the context of chronic liver disease and cirrhosis, these same regenerative signals are dysregulated, creating a favorable environment for the proliferation of cancer cells.

The upregulation of HGF and TGF-α in HCC patients demonstrates that growth factors intended to promote hepatocyte repair and regeneration are being hijacked by malignant cells to sustain tumor growth. This finding is consistent with previous research indicating that the regenerative capacity of the liver, while beneficial for tissue recovery, can inadvertently contribute to oncogenesis and tumor expansion when combined with chronic liver damage and inflammation.

Inflammatory cytokines, particularly IL-6 and TNF-α, were also significantly elevated in HCC patients. These cytokines are known to activate pro-survival and proliferative pathways, including STAT3 and NF-κB, which promote both liver regeneration and cancer cell survival. Chronic inflammation, a hallmark of liver diseases such as hepatitis B, hepatitis C, and non-alcoholic steatohepatitis (NASH), likely exacerbates this process, leading to continuous liver regeneration and, in turn, accelerated HCC growth.

The rapid tumor growth observed in HCC patients, with a 35% increase in tumor size over a 12-month period, underscores the importance of understanding the interplay between liver regeneration and cancer progression. The data suggest that higher levels of regenerative markers, particularly HGF and IL-6, are directly associated with faster tumor growth. This highlights the potential for therapeutic strategies targeting these pathways to slow tumor progression in patients with HCC. Drugs that inhibit

growth factor signaling, such as tyrosine kinase inhibitors, or anti-inflammatory therapies aimed at reducing IL-6 and TNF-α activity, could prove beneficial in managing HCC in patients with chronic liver disease.

This study contributes to the growing body of evidence that liver regeneration, while essential for maintaining liver function in the face of injury, also plays a critical role in the progression of liver cancer. The challenge lies in finding therapeutic approaches that preserve the liver's regenerative capacity while preventing the accelerated growth of malignant cells.

Conclusion

This study demonstrates the significant role of liver regeneration in the accelerated growth of hepatocellular carcinoma (HCC). The findings indicate that regenerative signals, such as growth factors (HGF and TGF-α) and inflammatory cytokines (IL-6 and TNF-α), which are critical for liver tissue repair, can also promote tumor growth in patients with chronic liver disease. The heightened expression of these markers in HCC patients, coupled with the observed 35% increase in tumor size over 12 months, underscores the need for targeted therapies that disrupt these regenerative pathways in order to slow HCC progression.

By identifying the key factors that link liver regeneration to cancer growth, this study paves the way for the development of novel treatments aimed at mitigating the effects of liver regeneration on tumor expansion. Such therapies could significantly improve outcomes for patients with HCC, particularly those with underlying liver diseases that drive continuous regeneration.

References

1. Teng CF, Chang HY, Tsai HW, Hsieh WC, Kuo YH, Su IJ, *et al*. Liver regeneration accelerates hepatitis B virus-related tumorigenesis of hepatocellular carcinoma. Molecular Oncology. 2018 Jun;12(7):1175-1187.
2. Nejak-Bowen KN, Thompson MD, Singh S, Bowen Jr WC, Dar MJ, Khillan J, *et al*. Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant β-catenin. Hepatology. 2010 May;51(5):1603-1613.
3. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010 Sep;29(36):4989-5005.
4. Thenappan A, Li Y, Kitisin K, Rashid A, Shetty K, Johnson L, *et al*. Role of transforming growth factor β signaling and expansion of progenitor cells in regenerating liver. Hepatology. 2010 Apr;51(4):1373-1382.
5. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. In: Seminars in Cancer Biology. 2011 Feb 1;21(1):44-58. Academic Press.
6. Barash H, Gross E, Edrei Y, Ella E, Israel A, Cohen I, *et al*. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proceedings of the National Academy of Sciences. 2010 Feb 2;107(5):2207-2212.
7. Michalopoulos GK, Bhushan B. Liver regeneration: biological and pathological mechanisms and implications. Nature Reviews Gastroenterology & Hepatology. 2021 Jan;18(1):40-55.
8. Park ES, Dezhbord M, Lee AR, Park BB, Kim KH. Dysregulation of liver regeneration by hepatitis B virus infection: impact on development of hepatocellular carcinoma. Cancers. 2022 Jul 22;14(15):3566.
9. Russell WE, Kaufmann WK, Sitaric S, Luetteke NC, Lee DC. Liver regeneration and hepatocarcinogenesis in transforming growth factor-α-targeted mice. Molecular Carcinogenesis. 1996 Mar;15(3):183-189.
10. Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, *et al*. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma. Nature Reviews Gastroenterology & Hepatology. 2012 Sep;9(9):530-538.
11. Jia C. Advances in the regulation of liver regeneration. Expert Review of Gastroenterology & Hepatology. 2011 Feb 1;5(1):105-121.